Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CIJ
|
|||
| Former ID |
DCL000550
|
|||
| Drug Name |
ISIS-CRP
|
|||
| Synonyms |
1-(Tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 172889-27-9; pp2; PP 2; 1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; AG 1879; 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; PP2; 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; AG-1879; CHEMBL406845; CHEBI:78331; AK-60369; 1-tert-butyl-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine; 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H16ClN5; 1qpe; 4few; PBBRWFOVCUAONR-UHFFFAOYSA-N; AG1879; PP 2 (AG 1879)
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 1 | [1] | |
| Inflammation [ICD-11: 1A00-CA43.1] | Phase 1 | [1] | ||
| Company |
ISIS Pharm
|
|||
| PubChem Substance ID |
842091, 1824409, 3198210, 5015937, 7980429, 8152998, 11121744, 11122224, 11362872, 11365434, 11367996, 11370955, 11370956, 11373597, 11376158, 14720328, 14898464, 17402368, 25784347, 26756748, 26756749, 26759387, 26759389, 29223959, 46393019, 47216596, 47588812, 47588813, 47736276, 47736277, 47959550, 50111406, 53787734, 53800584, 56373967, 57322499, 57581298, 78228220, 85787287, 85789462, 89704588, 90945043, 92310095, 99222858, 99234352, 99301007, 99302527, 103102516, 103219431, 103904781
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). | |||
| REF 3 | The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. | |||
| REF 4 | Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9. | |||
| REF 5 | Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.